Steroids use in Severe/ Life Threatening COVID-19 Pneumonia: Does the Type or Dose Matter?

IF 0.1 Q4 MEDICINE, GENERAL & INTERNAL
A. Arshad, B. Saeed, S. Hussain
{"title":"Steroids use in Severe/ Life Threatening COVID-19 Pneumonia: Does the Type or Dose Matter?","authors":"A. Arshad, B. Saeed, S. Hussain","doi":"10.21649/akemu.v28i4.5310","DOIUrl":null,"url":null,"abstract":"Objective: To compare the effect of different doses of methylprednisolone and dexamethasone on in-hospital mortality in severe COVID-19 pneumonia Methods: This retrospective chart review was done by reviewing old medical reports of patients with severe \ndisease admitted to COVID-19 Intensive Care and High Dependency Unit from October 2020 to September 2021. Those with suspected COVID-19 infection (suggestive radiological findings but negative PCR for SARSCoV- 2 on at least two occasions) were excluded. Patients requiring high flow oxygen (>6 liters per minute) or higher levels of respiratory support were classified as having severe disease. We recorded the type of steroids used and the doses. Methylprednisolone in doses up to 40mg per day, or other steroids in equivalent doses, were considered low dose. Primary outcome of interest was in- hospital mortality. Results: There were 279 patients aged 52.53± 11.31 years, including 216 (77.42%) males. Mean hospital stay was 10.18± 3.13 days. During hospital stay, 96 (34.41%) patients died. Amongst patients receiving dexamethasone, 70 (44.87%) expired, whereas 26 (21.14%) out of 123 patients who received methylprednisolone expired (p","PeriodicalId":43918,"journal":{"name":"Annals of King Edward Medical University Lahore Pakistan","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of King Edward Medical University Lahore Pakistan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21649/akemu.v28i4.5310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To compare the effect of different doses of methylprednisolone and dexamethasone on in-hospital mortality in severe COVID-19 pneumonia Methods: This retrospective chart review was done by reviewing old medical reports of patients with severe disease admitted to COVID-19 Intensive Care and High Dependency Unit from October 2020 to September 2021. Those with suspected COVID-19 infection (suggestive radiological findings but negative PCR for SARSCoV- 2 on at least two occasions) were excluded. Patients requiring high flow oxygen (>6 liters per minute) or higher levels of respiratory support were classified as having severe disease. We recorded the type of steroids used and the doses. Methylprednisolone in doses up to 40mg per day, or other steroids in equivalent doses, were considered low dose. Primary outcome of interest was in- hospital mortality. Results: There were 279 patients aged 52.53± 11.31 years, including 216 (77.42%) males. Mean hospital stay was 10.18± 3.13 days. During hospital stay, 96 (34.41%) patients died. Amongst patients receiving dexamethasone, 70 (44.87%) expired, whereas 26 (21.14%) out of 123 patients who received methylprednisolone expired (p
在严重/危及生命的COVID-19肺炎中使用类固醇:类型或剂量重要吗?
目的:比较不同剂量甲基强的松龙和地塞米松对COVID-19重症肺炎住院死亡率的影响方法:通过回顾2020年10月至2021年9月COVID-19重症监护高依赖病房收治的重症患者的旧医疗报告,进行回顾性图表复习。排除疑似COVID-19感染的患者(影像学提示,但PCR至少两次SARSCoV- 2阴性)。需要高流量氧气(>6升/分钟)或更高水平呼吸支持的患者被归类为重症患者。我们记录了使用类固醇的种类和剂量。甲基强的松龙的剂量为每天40毫克,或其他类固醇的剂量为同等剂量,被认为是低剂量。主要研究终点为住院死亡率。结果279例患者,年龄52.53±11.31岁,其中男性216例(77.42%)。平均住院时间10.18±3.13 d。住院期间死亡96例(34.41%)。在接受地塞米松治疗的患者中,70例(44.87%)患者死亡,而123例接受甲基强的松龙治疗的患者中,26例(21.14%)患者死亡(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
75
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信